Nicox SA announced that members of the management team will participate in the following financial, pharmaceutical industry and scientific conferences in Europe and U.S. in the coming months: Financial and pharmaceutical Industry conferences.
Press Release Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2022
January 27, 2022
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that members of the management team will participate in the following financial, pharmaceutical industry and scientific conferences in Europe and U.S. in the coming months:
Financial and pharmaceutical Industry conferences
- BIOMED Event - March 8, 2022 - Paris, France
- SmallCap Event - April 4-5, 2022, Paris, France
- Invest Access Event - April 4-5, 2022 - Paris, France
- BIO International Convention - June 13-16, 2022 - San Diego, U.S.
- Spring Midcap Event - June 23-24, 2022 - Paris, France
Members of the management team will be available for one-on-one meetings at these events.
Scientific conferences
- Glaucoma 360 – February 10-12, 2022, San Francisco, CA, U.S.
- American Glaucoma Society (AGS) 2022 Annual Meeting – March 3-6, 2022 – Nashville, TN, U.S.
- American Society of Cataract and Refractive Surgery (ASCRS) 2022 Annual Meeting – April 22-26, 2022 – Washington, DC, U.S.
- Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual meeting – May 1-5, 2022 – Denver, CA, U.S., May 11-12, 2022 – Virtual
- 15th European Glaucoma Society (EGS) Congress – June 4-8, 2022 – Athens, Greece
About Nicox Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. .
Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.
For more information on Nicox, its products or pipeline, please visit: www.nicox.com. Analyst coverage Bryan, Garnier & Co Dylan Van Haaften Paris, France
Edison Investment Research Pooya Hemami London, UK
H.C. Wainwright & Co Yi Chen New York, U.S.
Kepler Cheuvreux Damien Choplain Paris, France The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Contacts Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com Investors & Media
United States & Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
svonderweid@lifesciadvisors.com Forward-Looking Statements The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.
Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2020’ filed with the French Autorité des Marchés Financiers (AMF) on March 1, 2021 and in the 2nd chapter of the amendment to the “Document d’Enregistrement Universel, rapport financier annuel et rapport de gestion 2020” filed with the AMF on December 9, 2021 which are available on Nicox’s website (www.nicox.com). Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99
Attachment
